Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.720
-0.120 (-3.12%)
At close: Jul 8, 2026, 4:00 PM EDT
3.715
-0.005 (-0.13%)
Pre-market: Jul 9, 2026, 5:57 AM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 600 employees as of December 31, 2025. The number of employees decreased by 200 or -25.00% compared to the previous year.
Employees
600
Change (1Y)
-200
Growth (1Y)
-25.00%
Revenue / Employee
$110,680
Profits / Employee
-$932,960
Market Cap
1.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -200 | -25.00% |
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lakefront Biotherapeutics NV | 558 |
| Kardigan | 241 |
| Monte Rosa Therapeutics | 187 |
| Stoke Therapeutics | 170 |
| Precigen | 160 |
| AnaptysBio | 104 |
| Nanobiotix | 100 |
| Tyra Biosciences | 87 |
RXRX News
- 14 days ago - Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today - TheFly
- 21 days ago - Recursion Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 7 weeks ago - Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City - GlobeNewsWire
- 7 weeks ago - Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley - TheFly
- 2 months ago - Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts